查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571417

兒科糖尿病治療市場規模、佔有率、趨勢分析報告：按類型、治療方法、給藥途徑、通路、地區和細分市場預測，2024-2030年

Pediatric Diabetes Therapeutic Market Size, Share & Trends Analysis Report By Type (Type 1, Type 2), By Treatment (Insulin, GLP-1, Biguanide, SGLT2), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

兒童糖尿病治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球兒童糖尿病治療市場規模將達到221.4億美元，2024年至2030年複合年成長率為13.9%。

該市場的主要推動力是兒童糖尿病盛行率的上升以及對早期診斷和有效管理的日益關注。國際糖尿病聯盟 (IDF) 估計，到 2022 年，全球 875 萬名 1 型糖尿病 (T1D) 患者中，只有 152 萬人年齡在 20 歲以下。這種快速增加主要是由於遺傳傾向、環境因素和生活方式的改變。

糖尿病管理的技術進步預計將對市場成長產生正面影響。連續血糖監測儀 (CGM)、胰島素幫浦和人工胰臟系統等創新技術可以更好地控制血糖並降低併發症的風險。例如，2023 年 6 月，美國FDA 宣布將 Sinjardi（Metformin二甲雙胍和Empagliflozin）用於 10 歲及以上 2 型組合藥物(T2D) 兒童，以改善血糖控制，作為飲食和運動療法的輔助療法。藥物）和核准 （Empagliflozin）。此次核准預計將顯著擴大 2 型糖尿病兒童的治療選擇，並促進該藥物在臨床實踐中的廣泛採用。此次核准是擴大年輕患者獲得有效治療方法的機會的重要一步，從而改善疾病管理並改善長期健康結果。

此外，隨著人們對兒童疾病認知的提高和早期診斷，人們擴大採用各種治療方案，包括胰島素治療、雙胍類藥物、GLP-1 受體促效劑和 SGLT2 抑制劑。旨在改善兒童糖尿病治療機會的支持性政府措施和政策也正在推動市場發展。隨著世界兒科人口的持續成長和糖尿病盛行率的增加，預計在預測期內對糖尿病治療的需求將顯著成長。

小兒糖尿病治療市場報告亮點

  • 2023年，第一類細分市場的收益佔有率最大，為79.32%。這是由於 1 型疾病的發病率和盛行率不斷增加以及全球對新療法的高需求。
  • 在治療方法，胰島素細分市場佔最大佔有率，2023年將達35.88%。這是由於新的輸送系統的開發和商業化，可以安全有效地管理胰島素，而不會傷害兒科患者。
  • 依給藥途徑，2023年注射給藥市場佔最大佔有率，為62.50%。這是由於新的皮下和靜脈注射藥物被核准用於治療兒童糖尿病。
  • 按通路分類，零售藥房領域在2023年佔據市場最大佔有率，達47.49%。這可以歸因於諸如易於取得和可利用的藥物來補充兒科患者糖尿病治療處方箋優勢。
  • 2023 年，北美市場佔據主導地位，佔有率為 41.49%。這是由於先進的醫療基礎設施、兒童糖尿病盛行率不斷上升以及臨床試驗和治療的有利法規和報銷等因素造成的。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章小兒糖尿病治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 小兒糖尿病治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析

第4章小兒糖尿病治療市場：類型估計與趨勢分析

  • 全球兒科糖尿病藥物市場：類型儀表板
  • 全球兒科糖尿病藥物市場：類型變異分析
  • 按類型分類的收益
  • 類型1
  • 2型

第5章小兒糖尿病治療市場：治療方法評估及趨勢分析

  • 全球小兒糖尿病治療市場：治療方法儀表板
  • 全球兒童糖尿病治療市場：治療方法變異分析
  • 按治療方法的收益
  • 胰島素
  • GLP-1受體促效劑
  • 雙胍
  • SGLT2抑制劑
  • 其他

第6章小兒糖尿病治療藥物市場：給藥途徑估算及趨勢分析

  • 全球兒科糖尿病藥物市場：途徑儀表板
  • 全球兒科糖尿病藥物市場：給藥途徑變異分析
  • 按管理途徑的收益
  • 口服
  • 胃腸外的
  • 其他

第7章小兒糖尿病治療藥物市場：通路估算與趨勢分析

  • 全球兒科糖尿病藥物市場：通路儀表板
  • 全球兒科糖尿病治療藥物市場：通路波動分析
  • 按通路分類的收益
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章小兒糖尿病治療藥物市場：按產品、應用、最終用途和地區分類的估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • Key company market share analysis, 2023
    • Boehringer Ingelheim International GmbH.
    • Eli Lilly and Company
    • Sanofi
    • Vertex Pharmaceuticals Incorporated
    • Novo Nordisk A/S
    • AstraZeneca.
    • MannKind Corporation
    • Xeris Pharmaceuticals
    • Amphastar Pharmaceuticals, Inc.
Product Code: GVR-4-68040-446-7

Pediatric Diabetes Therapeutic Market Growth & Trends:

The global pediatric diabetes therapeutic market size is anticipated to reach USD 22.14 billion by 2030, growing at a CAGR of 13.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the rising prevalence of diabetes among children and the increasing focus on early diagnosis and effective management. The International Diabetes Federation (IDF) estimates that in 2022, out of the 8.75 million people living with type 1 diabetes (T1D) worldwide, only 1.52 million were under the age of 20. This surge is largely due to genetic predisposition, environmental factors, and changes in lifestyle patterns.

Technological advancements in diabetes management are anticipated to positively impact market growth. Innovations such as continuous glucose monitors (CGMs), insulin pumps, and artificial pancreas systems enable better glucose control, reducing the risk of complications. For example, in June 2023, the U.S. FDA approved Synjardy (a combination of metformin hydrochloride and empagliflozin) and Jardiance (empagliflozin) for use in children aged 10 and older with type 2 diabetic (T2D), as an adjunct to diet and exercise for better blood sugar control. This approval is expected to significantly enhance treatment options for pediatric with T2D, encouraging broader adoption of these medications in clinical practice. It marks a critical step in expanding access to effective therapies for younger patients, leading to improved disease management and better long-term health outcomes.

Furthermore, the growing awareness and early diagnosis of disease in children have led to an increase in the adoption of various treatment options, including insulin therapies, biguanides, GLP-1 receptor agonists, and SGLT2 inhibitors. The market is also driven by supportive government initiatives and policies aimed at improving access to diabetic care for children. As the global children population continues to rise, along with the increasing prevalence of diabetes, the demand for diabetic treatment is expected to grow significantly during the forecast period.

Pediatric Diabetes Therapeutic Market Report Highlights:

  • The type 1 segment held the largest revenue share of 79.32% in 2023. This can be attributed to the increasing incidence and prevalence of type 1 disease and high demand for new therapy treatment across worldwide.
  • In treatment, the insulin segment is held the largest share of 35.88% of the market in 2023. This can be attributed to the development and commercialization of novel delivery systems to deliver insulin safely and effectively to children's patients without harm.
  • In route of administration, the parenteral segment is held the largest share of 62.50% of the market in 2023. This can be attributed to the growing approval of new subcutaneous and intravenous medicine for treatment of pediatric diabetes patient.
  • In distribution channel, the retail pharmacies segment is held the largest share of 47.49% of the market in 2023. This can be attributed to its advantages such as easy accessibility and availability of medication to refill prescriptions of pediatric patients for diabetes treatment.
  • North America dominated the market in 2023 with a share of 41.49%, owing to factors such as advanced healthcare infrastructure, increasing prevalence of diabetic in children, and favorable regulatory and reimbursement for clinical trial and treatment.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and treatment outlook
    • 2.2.2. Route of administration and distribution channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Pediatric diabetes therapeutic market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of diabetic diseases in children
      • 3.2.1.2. Rising awareness about diabetes
      • 3.2.1.3. Advancement in treatment methodologies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Stringent regulations pertaining to drug approval
  • 3.3. Pediatric Diabetes Therapeutic Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Pediatric diabetes therapeutic market: Type Estimates & Trend Analysis

  • 4.1. Global Pediatric Diabetes Therapeutic Market: Type Dashboard
  • 4.2. Global Pediatric Diabetes Therapeutic Market: Type Movement Analysis
  • 4.3. Global Pediatric Diabetes Therapeutic Market By Type, Revenue (USD Million)
  • 4.4. Type 1
    • 4.4.1. Type 1 market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Type 2
    • 4.5.1. Type 2 market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pediatric diabetes therapeutic market: Treatment Estimates & Trend Analysis

  • 5.1. Global Pediatric Diabetes Therapeutic Market: Treatment Dashboard
  • 5.2. Global Pediatric Diabetes Therapeutic Market: Treatment Movement Analysis
  • 5.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
  • 5.4. Insulin
    • 5.4.1. Insulin market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. GLP-1 Receptor Agonists
    • 5.5.1. GLP-1 Receptor Agonists market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Biguanide
    • 5.6.1. Biguanide market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. SGLT2 Inhibitors
  • 5.8. SGLT2 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pediatric diabetes therapeutic market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Pediatric Diabetes Therapeutic Market: Route of Administration Dashboard
  • 6.2. Global Pediatric Diabetes Therapeutic Market: Route of Administration Movement Analysis
  • 6.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Parenteral
    • 6.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Pediatric diabetes therapeutic market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Global Pediatric Diabetes Therapeutic Market: Distribution Channel Dashboard
  • 7.2. Global Pediatric Diabetes Therapeutic Market: Distribution Channel Movement Analysis
  • 7.3. Global Pediatric Diabetes Therapeutic Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Pediatric diabetes therapeutic market: Regional Estimates & Trend Analysis By Product, Application, and End Use

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company market share analysis, 2023
    • 9.3.2. Boehringer Ingelheim International GmbH.
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Eli Lilly and Company
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Sanofi
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Vertex Pharmaceuticals Incorporated
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Novo Nordisk A/S
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. AstraZeneca.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. MannKind Corporation
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Xeris Pharmaceuticals
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Amphastar Pharmaceuticals, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America pediatric diabetes therapeutic market, by Type, 2018 - 2030 (USD Million)
  • Table 4 North America pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 North America pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 North America pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 U.S. pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S. pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 U.S. pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 12 Canada pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Canada pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Canada pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Mexico pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 16 Mexico pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Mexico pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Europe pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 21 Europe pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 22 Europe pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Germany pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 25 Germany pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Germany pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Germany pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 UK pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 29 UK pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 30 UK pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 UK pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 France pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 33 France pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 34 France pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 France pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Italy pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 37 Italy pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Italy pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Italy pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Spain pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 41 Spain pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Spain pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Spain pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Denmark pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 45 Denmark pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 Denmark pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Denmark pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Sweden pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 49 Sweden pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 50 Sweden pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 51 Norway pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 52 Norway pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 53 Norway pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 54 Norway pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 60 China pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 61 China pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 China pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63 China pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 Japan pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 65 Japan pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 66 Japan pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 67 Japan pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 68 India pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 69 India pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 70 India pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 71 India pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 South Korea pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 73 South Korea pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 74 South Korea pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 75 South Korea pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 76 Australia pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 77 Australia pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 78 Australia pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 79 Australia pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 Thailand pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 81 Thailand pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 82 Thailand pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 Thailand pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 Latin America pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
  • Table 85 Latin America pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 86 Latin America pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 87 Latin America pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 Latin America pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 89 Brazil pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 90 Brazil pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 91 Brazil pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 92 Brazil pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93 Argentina pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 94 Argentina pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 95 Argentina pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 96 Argentina pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 97 MEA pediatric diabetes therapeutic market, by region, 2018 - 2030 (USD Million)
  • Table 98 MEA pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 99 MEA pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 100 MEA pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 101 MEA pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 102 South Africa pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 103 South Africa pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 104 South Africa pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 105 South Africa pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 110 UAE pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 111 UAE pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 112 UAE pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 113 UAE pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 114 Kuwait pediatric diabetes therapeutic market, by type, 2018 - 2030 (USD Million)
  • Table 115 Kuwait pediatric diabetes therapeutic market, by treatment, 2018 - 2030 (USD Million)
  • Table 116 Kuwait pediatric diabetes therapeutic market, by route of administration, 2018 - 2030 (USD Million)
  • Table 117 Kuwait pediatric diabetes therapeutic market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Pediatric diabetes therapeutic market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Pediatric diabetes therapeutic market snapshot
  • Fig. 10 Pediatric diabetes therapeutic market driver impact
  • Fig. 11 Pediatric diabetes therapeutic market restraint impact
  • Fig. 12 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Value chain analysis
  • Fig. 15 Pediatric diabetes therapeutic market: Type Outlook and key takeaways
  • Fig. 16 Pediatric diabetes therapeutic market: Type movement analysis
  • Fig. 17 Type 1 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Type 2 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Pediatric diabetes therapeutic market: Treatment outlook and key takeaways
  • Fig. 20 Pediatric diabetes therapeutic market: Treatment movement analysis
  • Fig. 21 Insulin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 GLP-1 Receptor Agonists market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Biguanide market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 SGLT2 Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Pediatric diabetes therapeutic market: Route of administration outlook and key takeaways
  • Fig. 27 Pediatric diabetes therapeutic market: Route of administration movement analysis
  • Fig. 28 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Pediatric diabetes therapeutic market: Distribution channel outlook and key takeaways
  • Fig. 32 Pediatric diabetes therapeutic market: Distribution channel movement analysis
  • Fig. 33 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Global pediatric diabetes therapeutic market: Regional movement analysis
  • Fig. 37 Global pediatric diabetes therapeutic market: Regional outlook and key takeaways
  • Fig. 38 Global pediatric diabetes therapeutic market share and leading players
  • Fig. 39 North America, by country
  • Fig. 40 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. key country dynamics
  • Fig. 42 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Canada key country dynamics
  • Fig. 44 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico key country dynamics
  • Fig. 46 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 UK key country dynamics
  • Fig. 49 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Germany key country dynamics
  • Fig. 51 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 France key country dynamics
  • Fig. 53 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Italy key country dynamics
  • Fig. 55 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Spain key country dynamics
  • Fig. 57 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark key country dynamics
  • Fig. 59 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Sweden key country dynamics
  • Fig. 61 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Norway key country dynamics
  • Fig. 63 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 China key country dynamics
  • Fig. 66 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Japan key country dynamics
  • Fig. 68 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 India key country dynamics
  • Fig. 70 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand key country dynamics
  • Fig. 72 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 South Korea key country dynamics
  • Fig. 74 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Australia key country dynamics
  • Fig. 76 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Brazil key country dynamics
  • Fig. 79 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Argentina key country dynamics
  • Fig. 81 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 South Africa key country dynamics
  • Fig. 84 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Saudi Arabia key country dynamics
  • Fig. 86 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 UAE key country dynamics
  • Fig. 88 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Kuwait key country dynamics
  • Fig. 90 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Market share of key market players- pediatric diabetes therapeutic market